Amyloidosis Therapeutics Market Size To Surge USD 6.45 Bn By 2034

Table of Contents

The global amyloidosis therapeutics market size was valued at USD 2.94 billion in 2024 and is predicted to surge around 6.45 billion by 2034, growing at a CAGR of 8.18% from 2025 to 2034.

Get Sample Copy of Report@ https://www.precedenceresearch.com/sample/5710

Key Insights

North America accounted for the largest market share of 47% in 2024.
Asia Pacific is projected to witness the fastest growth rate from 2025 to 2034.
The chemotherapy segment emerged as the leading treatment category in 2024.
The transplantation segment is anticipated to expand rapidly during the forecast period.
Hospitals and clinics dominated the market by end user in 2024.
The home care settings segment is expected to register the highest growth rate over the next decade.

AI Advancing Diagnosis and Treatment in Amyloidosis Therapeutics

AI-powered diagnostic tools enhance early detection by analyzing imaging scans and biomarker data with higher accuracy.
Machine learning models predict disease progression, allowing for timely intervention and personalized treatment plans.
AI-driven drug discovery accelerates the identification of new therapeutic compounds, reducing research timelines and costs.
Natural language processing (NLP) helps analyze vast amounts of medical literature to find potential treatment strategies.
AI-integrated wearable devices monitor patient vitals in real time, improving remote care and reducing hospital visits.
Predictive analytics assist healthcare providers in identifying high-risk patients for proactive disease management.

Growth Factors:

Increasing Disease Prevalence: The rising incidence of amyloidosis, particularly among the aging population, has heightened the demand for effective therapeutic options.
Advancements in Diagnostic Techniques: Improvements in diagnostic procedures have facilitated earlier detection of amyloidosis, leading to timely interventions and better patient outcomes.
Development of Novel Therapies: Ongoing research and development efforts have resulted in innovative treatment modalities, including targeted therapies and monoclonal antibodies, enhancing the efficacy of amyloidosis management.
Increased Awareness and Screening: Growing awareness among healthcare professionals and patients has led to more frequent screenings, contributing to early diagnosis and treatment.

Regional Outlook:

North America: In 2024, North America dominated the global amyloidosis therapeutics market, accounting for a 47% share. This leadership is attributed to a well-established healthcare infrastructure, high awareness levels, and substantial investment in research and development.
Asia Pacific: The Asia Pacific region is projected to experience the fastest compound annual growth rate (CAGR) between 2025 and 2034. Factors such as improving healthcare facilities, increasing healthcare expenditure, and a growing patient population contribute to this rapid expansion.
Europe: Europe holds a significant share of the amyloidosis therapeutics market, driven by advanced diagnostic capabilities and a strong emphasis on rare disease management. The region’s focus on healthcare innovation supports market growth.
Latin America and Middle East & Africa: These regions are gradually emerging in the amyloidosis therapeutics market, with increasing awareness and improving healthcare infrastructures. However, challenges such as limited access to advanced treatments and economic constraints may affect growth rates.

Also Read: Medical Imaging Outsourcing Market

Market Scope

Report Coverage	Details
Market Size by 2034	USD 6.45 Billion
Market Size in 2025	USD 3.18 Billion
Market Size in 2024	USD 2.94 Billion
Market Growth Rate from 2025 to 2034	CAGR of 8.18%
Dominated Region	North America
Fastest Growing Market	Asia Pacific
Base Year	2024
Forecast Period	2025 to 2034
Segments Covered	Treatment, End User, and Regions.
Regions Covered	North America, Europe, Asia-Pacific, Latin America and Middle East & Africa

Market Dynamics

Market Drivers

The demand for amyloidosis therapeutics is increasing due to a higher incidence of amyloid-related diseases and advancements in genetic research. Enhanced diagnostic methods, such as AI-powered imaging and biomarker detection, are improving early diagnosis rates. The growing collaboration between pharmaceutical companies and research institutions is also leading to the development of innovative treatment approaches.

Market Opportunities

The emergence of targeted therapies and immunotherapies presents a significant growth opportunity in the market. Personalized medicine approaches are becoming more viable, allowing for customized treatments based on a patient’s genetic profile. Additionally, government initiatives and funding for rare disease research are driving investment in new drug development.

Market Challenges

Limited patient access to advanced treatments, particularly in low-income countries, remains a significant hurdle. The rarity of the disease results in a smaller market size, making drug development less attractive for some pharmaceutical companies. Regulatory challenges and lengthy approval processes for new therapies further slow down market growth.

Amyloidosis Therapeutics Market Companies

Alnylam Pharmaceuticals, Inc.
Amgen Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd
GSK plc.
Takeda Pharmaceutical Company Limited
Sanofi
Pfizer Inc.
Johnson & Johnson Services, Inc.
Merck KGaA
Novartis AG
Ionis Pharmaceuticals

Leader’s Announcements

In March 2025, Ionis Pharmaceuticals Inc., announced the European Union’s approval for Ionis and AstraZeneca’s WAINZUA (eplontersen). Brett P. Monia, Chief Executive Officer, Ionis, said that, “Today’s approval of WAINZUA in Europe offers adults with hereditary transthyretin-mediated amyloidosis with polyneuropathy a new, self-administered treatment option that provides consistent suppression of transthyretin production and improves neuropathy impairment and quality of life. With approvals in North America, UK and now across the EU, we are proud of the continued progress as we and our partner, AstraZeneca, rapidly and effectively deliver WAINZUA to people around the world.”

Recent Developments

In February 2025, Paradox Immunotherapeutics, a pharmaceutical company developing innovative antibody therapies, secured a $10 million investment in a financing round led by SymBiosis which is an investment firm concentrated on advancing biotherapeutics innovations for serious and life-threatening diseases. The funding will focus on advancing therapies for protein misfolding diseases and accelerating candidates for immunoglobulin light chain amyloidosis (AL amyloidosis) and leukocyte chemotactic factor 2 amyloidosis (LECT2).
In July 2024, Kisunla which is a first-of-a-kind amyloid plaque removal therapy developed by Eli Lilly and Company for treatment of adults with early symptoms of Alzheimer’s disease and confirmed amyloid pathology received approval from the U.S. FDA.

Segments Covered in the Report

By Treatment

Chemotherapy
Immunosuppressive Drugs
Transplantation
Supportive Care
Surgery
Others

By End User

Hospitals & Clinics
Ambulatory Surgical Centers
Home Care Settings
Others

By Region

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Ready for more? Dive into the full experience on our website@ https://www.precedenceresearch.com/

Author
Recent Posts

akshay dhamal